{
    "relation": [
        [
            "",
            "Number of Participants Analyzed [units: participants]",
            "Mean Percent Changes From Baseline in Fasting Total Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Non-HDL Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, and Triglycerides at Week 96 [units: percent change] Mean (Standard Deviation)",
            "Total Cholesterol (n=29)",
            "HDL Cholesterol (n=29)",
            "Non-HDL Cholesterol (n=29)",
            "LDL Cholesterol (n=28)",
            "Triglycerides (n=29)"
        ],
        [
            "Atazanavir (ATV)/Ritonavir (RTV) Monotherapy.",
            "61",
            "",
            "14 (17.4)",
            "2 (21.2)",
            "19 (23.7)",
            "29 (34.4)",
            "16 (67.2)"
        ]
    ],
    "pageTitle": "Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00337467?sect=Xi015&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988860.4/warc/CC-MAIN-20150728002308-00236-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 872859874,
    "recordOffset": 872843935,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Participant Flow: \u00a0 Overall Study ATV/RTV treatment regimen was administered once daily. ATV: 2 x 150 mg capsules once daily with food (meal or snack), RTV: 1 x 100 mg capsule once daily with food (meal or snack) Atazanavir (ATV)/Ritonavir (RTV) Monotherapy. Description \u00a0 Reporting Groups 63 participants were enrolled in this study; 2 were never treated (1 no longer met study criteria and 1 concomitant medication not permitted). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow",
    "textAfterTable": "Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Subject No Longer Met Study Criteria \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 [1] 5 of these participants discontinued prior to Week 48 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description Atazanavir (ATV)/Ritonavir (RTV) Monotherapy. ATV/RTV treatment regimen was administered once daily. ATV: 2 x 150 mg capsules",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}